Royalty Report: Drugs, Diabetes Treatment – Collection: 289232

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 4

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 4

Primary Industries

  • Drugs
  • Diabetes Treatment

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 289232

License Grant
Licensor hereby grants to Japanese Licensee an exclusive license with sublicensing rights under Licensed Technology, to research, develop, formulate, make, have made, use, sell, offer for sale, import and export Products in the Field of Use in the Licensed Territory.

Licensee hereby grants to Licensor an exclusive license with sublicensing rights under Licensee Technology, to research, develop, formulate, make, have made, use, sell, offer for sale, import and export Products in the Field of Use in the Licensor Territory.

License Property
Product(s) shall mean pharmaceutical products containing NBI-6024 as an active component.

Licensed Patent Rights shall mean the patents and patent applications listed and any Patent Rights based thereon.
US Patent #5,594,100 – Epitope for prevention of type I diabetes
US Application #09/255,668 – Methods for treating diabetes using peptide analogs

Licensed Technology shall mean any technology, trade secrets, know-how and other intellectual property (other than Trademarks) directed to products, processes, formulations and/or methods and any biological materials owned or Controlled on the Effective Date or to be owned or Controlled thereafter by Licensor or its Affiliates which are necessary to research, develop, formulate, make, use or sell  NBI-6024 and shall include the Licensed   Patent Rights, Licensor Data and Manufacturing Technology.

Licensor Data shall mean the pre-clinical and clinical data collected by Licensor or its Affiliates in support of the CTX.

CTX shall mean the NBI-6024 CTX filed by Licensor with the Medicines Control Agency in the United Kingdom on December 15, 1998.

NBI-6024 shall mean altered peptide ligand as defined by the amino acid sequence set forth.  NBI-6024 is the acetate salt of a synthetic peptide of 15 naturally occurring amino acids based on a sequence derived from the B chain of human insulin.  All GLP safety studies and proposed clinical studies will use fully characterized GMP material.

Manufacturing Technology shall mean technology and know-how owned or Controlled by Licensor or its Affiliates  which relate to the manufacture of NBI-6024 as set forth in the CTX  and any other technology, know-how or standard operating procedures implemented by Licensor or its Affiliates which are actually being used by Licensor or its Affiliates to manufacture Products during the term of this Agreement.

Taisho Technology shall mean any technology, trade secrets, know-how and other intellectual property (other than  Trademarks) directed to products, processes, formulations and/or methods and any biological materials owned or Controlled on the Effective Date or to be owned or Controlled thereafter by Taisho or its Affiliates which are necessary to research, develop, formulate, make, useor sell NBI-6024.

Patent Right shall mean patent applications, patents issuing thereon and any extensions or restorations by existing or future extension or restoration mechanisms including Supplementary Protection Certificates or the equivalent   thereof, renewals, continuations, continuations-in-part, divisions, patents-of-addition, and/or reissues of any patent, which have not lapsed, been canceled or become abandoned and have not been declared invalid or  unenforceable by an unreversed and unappealable decision or judgement of a court or other appropriate body of competent jurisdiction.

Field of Use
Field of Use shall mean with respect to a pharmaceutical product, all human therapeutic and prophylactic uses of that product. The Field of Use shall not include diagnostic uses of a product.

IPSCIO Record ID: 211927

License Grant
The Licensor and Japanese Licensee entered into the License Agreement pursuant to which Licensor granted the Licensee exclusive rights to Licensors proprietary altered peptide ligand, NBI-6024, in the Field of Use in Asian and European countries.

The parties now wish to amend the License Agreement to provide for collaboration between Licensor and Licensee in the development of NBI-6024 and to provide to Licensee exclusive commercialization rights to NBI-6024 in the Licensor Territory.

On execution of this Agreement, Licensee shall purchase rights to the CTX filing for NBI-6024 and all supporting data and information for use in exploitation of the Asian rights granted hereunder and rights to the CTX filing for NBI-6024 and all supporting data and information for use in exploitation of the European rights granted hereunder.

License Property
On execution of this Agreement, Licensee shall purchase rights to the CTX filing for NBI-6024 and all supporting data and information for use in exploitation of the Asian rights granted hereunder and rights to the CTX filing for NBI-6024 and all supporting data and information for use in exploitation of the European rights granted hereunder.

NBI-6024 is a diabetes vaccine that is composed of an altered peptide ligand (APL) which is a dominant pancreatic antigen engineered so that it no longer can be recognized by autoreactive immune cells.

Field of Use
'Field of Use' shall mean with respect to a pharmaceutical product, all human therapeutic and prophylactic uses of that product.

NBI-6024 is the peptide whose insulin construction is altered using Licensor's proprietary altered peptide ligand (APL) technology; developments for its application in treating type 1 diabetes are advancing.

IPSCIO Record ID: 279366

License Grant
Licensor hereby grants to Licensee the exclusive worldwide right and license, with the right to sublicense on the terms and conditions set forth, in the Field of Use under the Licensor Patent(s) to make, have made, market, have marketed, use, import, offer for sale, sell and have sold Licensed Product (the License). The License granted hereunder shall be subject to any rights of the U.S. Government, its agencies or authorities under Public Law 96-517 and Public Law 98-620 which may be applicable. Notwithstanding the License granted herein, Licensor shall have the right, subject to Licensees consent, not to be unreasonably withheld, to make and have made Licensed Product(s) for itself and distribution to non-profit organizations for research purposes only, but not for any commercial or other purpose. Nothing in the foregoing sentence shall constitute a grant by Licensee or confer upon Licensor any rights to make or use the Biological Materials.
License Property
Licensor Patent(s) shall mean those United States or foreign patents and/or applications listed hereto as amended and modified from time to time by Licensor is hereby incorporated herein by reference, the inventions disclosed therein, and any divisions, reissues, continuations, continuations-in-part or extensions relating or corresponding thereto, and disclosed in foreign patent application corresponding thereto.

US Application Serial No. 09/546,733  

Biological Materials shall mean the vascular endothelial growth factor-2 gene referred to as “VEGF-2” and proprietary naked plasmid DNA encoding for VEGF-2, including the plasmid DNA sometimes referred to as “phVEGF-2” or “pVGI.1(VEGF2)”, together with any Progeny, Derivatives and Modifications therefrom.

Initial Product shall mean a product for the treatment of peripheral diabetic neuropathy that incorporates Biological Materials.

Licensed Product shall mean any product or method in the Field of Use covered by one or more Valid Claims.

Intellectual Property shall mean all intellectual property rights, including (i) United States and other national patents and patent applications, divisions, continuations, continuations-in-part, reissues, renewals, reexaminations, requests for continued examination, supplemental registrations or extensions thereof, (ii) trademarks, whether registered or unregistered and applications for registration thereof, (iii) copyrights, whether registered or unregistered and applications for registration thereof, and (iv) trade secrets, know-how, technology, proprietary information and data, including formulae, procedures, plans, methods, processes, specifications, models, protocols, techniques and experimentation, and design, testing and manufacturing data, and products, compositions, and procedures.

Field of Use
Field of Use shall mean the use of Biological Materials for treating a peripheral neuropathy, including, without limitation, diabetic neuropathy.

Peripheral neuropathy refers to the conditions that result when nerves that carry messages to and from the brain and spinal cord from and to the rest of the body are damaged or diseased. The peripheral nerves make up an intricate network that connects the brain and spinal cord to the muscles, skin, and internal organs.

IPSCIO Record ID: 286081

License Grant
Japanese Licensor hereby grants to Licensee a co-exclusive license under Licensed Patent Rights, to develop, make, have made, use, label, promote, distribute and sell Licensed Product in the territory.
License Property
Licensed Patent Rights shall mean (a) the patents and patent applications listed hereto and any continuations, divisions, reexaminations or reissues thereof, and any registration, revalidation or other equivalents based thereon, and (b) any patent extensions, and supplementary or complementary protection certificates or applications therefor based thereon.

U.S. Patent #5,674,845 – Treatment of insulin-resistant diabetes

Licensed Product shall mean any and all finished pharmaceutical product(s) which contains IGF-I (“IGF-I Product”), including, but not limited to, rhIGF-I/rhIGFBP-3, as the therapeutic or prophylactic active ingredient and which when developed, made, used, labeled, promoted, distributed or sold would, but for the license granted hereunder, infringe a valid claim.

Indications shall mean any and all insulin resistant diabetes claimed in the Licensed Patent Rights which are (1) Type A insulin resistant diabetes, (ii) Mendenhalls syndrome, (iii) Werner Syndrome, (iv) eleprechaunism, (v) lipoatrophic diabetes, and (vi) other indications which both parties agree from time to time to be included within the scope of the claims of the Licensed Patent Rights by good faith scientific and legal judgment.

Field of Use
This agreement pertains to the drug industry.  Treatment shall mean, with respect to a particular indication or other medical condition, the cure, reduction, mitigation, preventing, slowing or halting the progress of, or otherwise management of such indication or medical condition or the symptoms thereof.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.